Product Description
Vactosertib is an orally bioavailable inhibitor of the serine/threonine kinase, transforming growth factor (TGF)-beta receptor type 1 (TGFBR1), also known as activin receptor-like kinase 5 (ALK5), with potential antineoplastic activity. Upon oral administration, vactosertib inhibits the activity of TGFBR1 and prevents TGF-beta/TGFBR1-mediated signaling. This suppresses tumor growth in TGFBR1-overexpressing tumor cells. TGFBR1, which is overexpressed in a variety of tumor cell types, plays a key role in tumor cell proliferation. Expression of TGF-beta promotes tumor cell proliferation, enhances the migration of tumor cells and suppresses the response of the host immune system to tumor cells. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Vactosertib)
Mechanisms of Action: TGFb Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: MedPacto
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Korea, United States
Active Clinical Trial Count: 6
Highest Development Phases
Phase 2: Adenocarcinoma|Colorectal Cancer|Esophageal Cancer|Fibromatosis, Aggressive|Gastrointestinal Cancer|Non-Small-Cell Lung Cancer|Osteosarcoma|Transitional Cell Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MP-VAC-209 | P2 |
Recruiting |
Osteosarcoma |
2025-07-01 |
23% |
| MP-VAC-204 | P2 |
Active, not recruiting |
Adenocarcinoma|Esophageal Cancer|Colorectal Cancer|Gastrointestinal Cancer |
2024-05-31 |
23% |
| MP-VAC-202 | P2 |
Not yet recruiting |
Transitional Cell Carcinoma |
2023-12-30 |
55% |
| NCT04656002 | P2 |
Not yet recruiting |
Adenocarcinoma|Gastrointestinal Cancer |
2023-12-01 |